TERT mutations were detected in 10.9% (43/393) of DTC patients, 9.8% (32/327) of PTC patients, and 16.7% (11/66) of FTC patients (Table 1 and Table 2). This evidence concerns the gene TERT and thyroid cancer, nonmedullary, 2.